Artrya — Investor Presentation (March 2025)

5 slides from Artrya's investor presentation, Mar 31, 2025

Slide 1: FDA Clearance for Salix Coronary Anatomy
For personal use only FDA Clearance for Salix® Coronary Anatomy 31 March 2025 1
Slide 2: Artrya secures milestone US FDA clearance for Salix Coronary Anatomy
Artrya secures milestone US FDA clearance for Salix® Coronary Anatomy • The Food and Drug Administration (FDA) 510(k) has cleared Salix® Coronary Anatomy (SCA) for commercial sale in the US • Artrya will now look to accelerate commercialisation of SCA with our existing strategic partners in US • Art
Slide 3: Salix is built to target all pillars across the care continuum
Salix® is built to target all pillars across the care continuum Artrya’s product pipeline goes further & moves us towards predicting the patient at risk. For personal use only Whole Heart Disease Structural Optimised Characterisation Severity Assessment Procedure Detailed Plaque and Dispersion Non-i
Slide 4: SAPPHIRE Study
SAPPHIRE Study Salix-based Analysis of Plaque to identify Patients at HIgher Risk of Events SAPPHIRE aims to: For personal use only 1) validate the prognostic value a novel plaque dispersion score (PDS), and 2) demonstrate that the PDS can be used guide medical therapy Study Overview Clinical Benefi
Slide 5: Thank You
For personal use only 5 Thank You